NEI
DNLI icon

Northwest & Ethical Investments’s Denali Therapeutics DNLI Stock Holding History

Northwest & Ethical Investments’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-68,643
Closed -$2M – 519
2024
Q3 		$2M Sell
68,643
-7,192
-9% -$178K 0.05% 251
2024
Q2 		$1.76M Hold
75,835
– – 0.05% 257
2024
Q1 		$1.56M Buy
75,835
+4,551
+6% +$85.5K 0.04% 265
2023
Q4 		$1.53M Sell
71,284
-3,484
-5% -$69K 0.05% 251
2023
Q3 		$1.54M Hold
74,768
– – 0.05% 249
2023
Q2 		$2.21M Sell
74,768
-17,729
-19% -$498K 0.07% 240
2023
Q1 		$2.13M Sell
92,497
-2,366
-2% -$65.1K 0.07% 252
2022
Q4 		$2.64M Buy
94,863
+14,983
+19% +$446K 0.09% 217
2022
Q3 		$2.45M Hold
79,880
– – 0.1% 216
2022
Q2 		$2.35M Hold
79,880
– – 0.09% 221
2022
Q1 		$2.57M Buy
79,880
+48,280
+153% +$1.66M 0.08% 229
2021
Q4 		$1.41M Buy
+31,600
New +$1.5M 0.04% 267

Other funds holding DNLI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Northwest & Ethical Investments's DNLI Position: Q4 2024 in Review

Northwest & Ethical Investments sold out of Denali Therapeutics (DNLI) in Q4 2024, closing a stake of 68,643 shares — an estimated $2M sold.

Northwest & Ethical Investments first reported a position in DNLI in Q4 2021 and held it in 12 quarters. The position peaked at $2.64M in Q4 2022. 223 funds tracked by Wall St. Rank hold DNLI as of Q4 2024.

  • Northwest & Ethical Investments reported no remaining Denali Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Northwest & Ethical Investments sold 68,643 Denali Therapeutics shares in Q4 2024, an estimated $2M.
  • Northwest & Ethical Investments first reported a position in Denali Therapeutics in Q4 2021 and held it in 12 quarters.
  • Northwest & Ethical Investments's Denali Therapeutics position peaked at $2.64M in Q4 2022.
  • 223 funds tracked by Wall St. Rank held Denali Therapeutics as of Q4 2024.

Based on Northwest & Ethical Investments's 13F filing for Q4 2024, filed 11 Feb 2025.